H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 13/01/2026 GMT			5-day change	1st Jan Change
44.08 ^DKK	+0.14%		+3.47%	+2.13%

01-07	Barclays Lowers Price Target for Lundbeck to 50 Danish Kroner (from 53), Maintains Equal Weight - BN	FW
12-08	Lundbeck Reports Long-Term Positive Phase 2 Data for Bexicaserin in Rare Pediatric Epilepsies	FW

Lundbeck, Otsuka's PTSD Treatment Combination Fails to Win US FDA Committee Recommendation

Published on 07/21/2025 at 04:38 am BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about H. Lundbeck A/S

01-07	Barclays Lowers Price Target for Lundbeck to 50 Danish Kroner (from 53), Maintains Equal Weight - BN	FW
12-08	Lundbeck Reports Long-Term Positive Phase 2 Data for Bexicaserin in Rare Pediatric Epilepsies	FW
12-06	H. Lundbeck A/S Announces Positive Phase 2 Long-Term Data for Bexicaserin in Rare Childhood-Onet Epilepsies, at American Epilepsy Society Annual Meeting	CI
12-03	BNP Paribas Exane Raises Price Target for Lundbeck to 45 Danish Kroner, Reiterates Neutral Rating - BN	FW
12-02	H. Lundbeck A/S Presents Comprehensive New Bexicaserin Dataset Epilepsies	CI
12-02	Lundbeck Presents Promising Data for New Epilepsy Drug	FW
11-26	Lundbeck Will Not Raise Its Bid for Avadel	FW
11-20	UBS Raises Lundbeck Target Price to 46 Danish Kroner, Maintains Neutral Rating	FW
11-19	Alkermes Raises Offer for Avadel to $22.50 Per Share	FW
11-18	H. Lundbeck A/S (CPSE:HLUN B) cancelled the acquisition of Avadel Pharmaceuticals plc.	CI
11-18	Barclays Raises Price Target for Lundbeck to 53 Danish Kroner, Reiterates Equal Weight	FW
11-17	Avadel Pharmaceuticals Board Deems Lundbeck's Takeover Proposal Superior	FW
11-14	H Lundbeck lifts guidance again as migraine and depression drugs drive growth
11-14	H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc for $2.1 billion.	CI
11-14	Lundbeck Makes Bid for Irish Firm Avadel Pharmaceuticals	FW
11-14	Lundbeck's New Drug Application for Migraine Preventive Drug Accepted by Japanese Ministry	MT
11-14	Lundbeck Seeks Market Approval for Vyepti in Asia	FW
11-14	H. Lundbeck A/S Announces the Acceptance of Its New Drug Application	CI
11-13	Kepler Cheuvreux Raises Target Price for Lundbeck to 65 Danish Kroner, Reiterates Buy	FW
11-13	SEB Raises Price Target for Lundbeck to 50 Danish Kroner, Reiterates Hold	FW
11-12	H. Lundbeck A/S, Q3 2025 Earnings Call, Nov 12, 2025
11-12	Nordea Raises Target Price for Lundbeck to 72 Danish Kroner (71), Reiterates Buy	FW
11-11	H. Lundbeck A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	H. Lundbeck A/S Increases Revenue Guidance for Full Year of 2025	CI
11-11	H. Lundbeck Upgrades FY25 Revenue Outlook	MT

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Employees

5,700

Sector

Pharmaceuticals

Calendar

02-10 - Q4 2025 Earnings Release (Projected)

More about the company